Pharma Focus Asia

Innovent Enters into Clinical Trial Collaboration with RemeGen

Monday, June 26, 2023

Innovent and RemeGen have entered into a clinical trial collaboration to investigate a combination therapy involving TYVYT® (sintilimab injection), an immune checkpoint inhibitor, and novel antibody-drug conjugate (ADC) candidates.

The collaboration between Innovent Biologics and RemeGen introduces an innovative treatment approach by combining RC88 and RC108 with sintilimab.

As part of their agreement, Innovent Biologics will be responsible for supplying TYVYT® (sintilimab injection) as the clinical drug for the collaboration. On the other hand, RemeGen will take the lead in conducting Phase 1/2a clinical studies to assess the safety and anti-tumour activity of combining TYVYT® with either RC88 or RC108. These clinical trials will specifically focus on Chinese patients diagnosed with advanced solid tumours.

This collaboration will focus to explore the potential of combination therapies involving TYVYT® (sintilimab injection) in conjunction with two promising antibody-drug conjugates (ADCs): RC88, which targets mesothelin (MSLN), and RC108, which targets c-Met. These novel ADCs have shown promise in targeting advanced solid tumours.

TYVYT® (sintilimab injection) is a groundbreaking PD-1 inhibitor renowned for its innovative approach to cancer treatment. It has garnered approval for an impressive seven indications in China and has been included in the esteemed National Reimbursement Drug List (NRDL) for six of these indications. 

Notably, TYVYT® (sintilimab injection) stands out as the sole PD-1 inhibitor recommended for first-line treatment in five high-incidence cancer types listed in the NRDL. These cancer types include non-squamous NSCLC, squamous NSCLC, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024